Plaque analysis is now formally recognised, widely accepted, and reimbursable by insurers in the US, including Medicare.

Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.